Viking Therapeutics, Inc. - Common Stock (VKTX)

These biotech businesses look compelling for very different reasons.

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

Viking Therapeutics shares fall in Wednesday's after-hours session after the company reported financial results for the second quarter.

Viking Therapeutics reports wider Q2 2025 loss, missing EPS estimates, causing a 5.7% after-hours dip. Focus remains on clinical pipeline progress amid revenue challenges.

Yet another biopharma name has been run through a familiar trading cycle that often ends on a bullish note.

The company announced a new drug that uses the same mechanism as Eli Lilly's retatrutide.

Timing matters with biotech stocks; these three companies offer distinct risk-reward profiles but have upcoming catalysts that could redefine their value